Two Sigma Investments
OMED

Two Sigma Investments’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Two Sigma Investments’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-14,738
Closed -$11K – 3702
2018
Q4 		$11K Sell
14,738
-8,200
-36% -$12.3K ﹤0.01% 2899
2018
Q3 		$49K Sell
22,938
-4,956
-18% -$11.9K ﹤0.01% 3099
2018
Q2 		$64K Buy
27,894
+3,357
+14% +$9.78K ﹤0.01% 3226
2018
Q1 		$78K Sell
24,537
-36,828
-60% -$101K ﹤0.01% 3054
2017
Q4 		$252K Buy
61,365
+37,205
+154% +$162K ﹤0.01% 2813
2017
Q3 		$109K Sell
24,160
-107,707
-82% -$436K ﹤0.01% 2644
2017
Q2 		$439K Buy
+131,867
New +$547K ﹤0.01% 2418
2014
Q1 		– Sell
-10,172
Closed -$300K – 2576
2013
Q4 		$300K Buy
+10,172
New +$186K ﹤0.01% 1881

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments's OMED Position: Q1 2019 in Review

Two Sigma Investments sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 14,738 shares — an estimated $11K sold.

Two Sigma Investments first reported a position in OMED in Q4 2013 and held it in 8 quarters. The position peaked at $439K in Q2 2017. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

  • Two Sigma Investments reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Two Sigma Investments sold 14,738 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $11K.
  • Two Sigma Investments first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 8 quarters.
  • Two Sigma Investments's OncoMed Pharmaceuticals, Inc. position peaked at $439K in Q2 2017.
  • 41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Two Sigma Investments's 13F filing for Q1 2019, filed 15 May 2019.